argenx SE (ARGX): Price and Financial Metrics


argenx SE (ARGX)

Today's Latest Price: $252.74 USD

1.60 (-0.63%)

Updated Oct 29 1:35pm

Add ARGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ARGX Stock Summary

  • ARGX's price/sales ratio is 140.27; that's higher than the P/S ratio of 97.84% of US stocks.
  • Over the past twelve months, ARGX has reported earnings growth of 640.7%, putting it ahead of 97.52% of US stocks in our set.
  • As for revenue growth, note that ARGX's revenue has grown 374.98% over the past 12 months; that beats the revenue growth of 98.19% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Argenx Se, a group of peers worth examining would be DNLI, FATE, PRQR, ASND, and AUTL.
  • ARGX's SEC filings can be seen here. And to visit Argenx Se's official web site, go to www.argenx.com.

ARGX Stock Price Chart Interactive Chart >

Price chart for ARGX

ARGX Price/Volume Stats

Current price $252.74 52-week high $284.00
Prev. close $254.34 52-week low $103.75
Day low $249.57 Volume 68,475
Day high $253.59 Avg. volume 176,318
50-day MA $248.09 Dividend yield N/A
200-day MA $198.13 Market Cap 11.88B

argenx SE (ARGX) Company Bio


arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.

ARGX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$252.74$2687.23 957%

We started the process of determining a valid price forecast for Argenx Se with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Argenx Se ranked in the 84th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Argenx Se ended up being:

  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 1.85% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Argenx Se's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1,274.91. This coverage rate is greater than that of just 0.38% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Argenx Se experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%936%
1%946%
2%957%
3%967%
4%977%
5%988%

Want more companies with a valuation profile/forecast similar to that of Argenx Se? See HCA, NVCR, NHC, FVE, and VMD.


ARGX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARGX Latest Social Stream


Loading social stream, please wait...

View Full ARGX Social Stream

Latest ARGX News From Around the Web

Below are the latest news stories about Argenx Se that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

J&J takeout of Momenta lifts argenx SE

Thinly traded argenx SE (ARGX) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (JNJ) $6.5B takeout of Momenta Pharmaceuticals (MNTA).The Belgian biotech's antibody engineering technology is similar to Momenta's, both involving the Fc region where antibodies modulate other cells in the immune system.In May, argenx reported...

Seeking Alpha | August 19, 2020

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

argenx SE (ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer Conference Call Participants Yaron Werber - Cowen Yatin...

SA Transcripts on Seeking Alpha | August 2, 2020

argenx reports half year 2020 financial results and provides second quarter business update

* Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be presented at upcoming medical meeting in 2020 * Cusatuzumab development strategy aligned with evolving AML treatment landscape to focus on combination with venetoclax and azacitidine * €1.9 billion in cash and cash equivalents and current financial assets strongly support commercial launch preparation of efgartigimod * Management to host conference call today at 2:30 pm CEST (8:30 am ET) July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On argenx SE (ARGX) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 20, 2020

argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | July 1, 2020

Read More 'ARGX' Stories Here

ARGX Price Returns

1-mo -2.87%
3-mo 9.82%
6-mo 73.68%
1-year 108.82%
3-year 975.49%
5-year N/A
YTD 57.45%
2019 67.09%
2018 52.15%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.818 seconds.